Immunohistochemical Detection of V600E BRAF Mutation is a Useful Primary Screening Tool for Malignant Melanoma.

CONCLUSION: The data revealed a close link between the two methods, supporting the use of the V600E as a primary screen for BRAF mutations in malignant melanoma. Negative results would be recommended for DNA probe testing. V600E antibody is considerably cheaper than the DNA probe assay. The BRAF IHC test can be performed within 24-48 hours, faster than the DNA probe assay enabling patients to receive faster treatment with improved turnaround times. Finally IHC detection is conserving of patient DNA from tumour blocks as only one section is required to perform the assay. PMID: 30870099 [PubMed - as supplied by publisher]
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research